Literature DB >> 23255402

Children's Oncology Group's 2013 blueprint for research: stem cell transplantation.

Stephan A Grupp1, Christopher C Dvorak, Michael L Nieder, John E Levine, Donna A Wall, Bryan Langholz, Michael A Pulsipher.   

Abstract

The role of SCT in pediatric oncology has continued to evolve with the introduction of new therapeutic agents and immunological insights into cancer. COG has focused its efforts on the study of hematopoietic stem cell transplantation in the treatment of pediatric malignancies in several major multi-institutional Phase II and Phase III studies. These studies include addressing the impact of allogenicity in ALL (ASCT0431), and establishing autologous stem cell transplant as the standard of care in neuroblastoma. Reducing transplant-associated toxicity was addressed in the ASCT0521 study, where the TNFα inhibitor etanercept was tested for the treatment of idiopathic pneumonia syndrome. Impact of cell dose was explored in the single versus tandem umbilical cord blood study CTN-0501, in close collaboration with the BMT-CTN.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh：

Year:  2012        PMID： 23255402      PMCID： PMC4064788          DOI： 10.1002/pbc.24437

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN： 1545-5009            Impact factor:   3.167


  17 in total

1.  Etanercept (Enbrel) administration for idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation.

Authors:  Gregory Yanik; Beth Hellerstedt; Joseph Custer; Raymond Hutchinson; Deborah Kwon; James L M Ferrara; Joseph Uberti; Kenneth R Cooke
Journal:  Biol Blood Marrow Transplant       Date:  2002       Impact factor: 5.742

2.  Treatment of advanced leukemia in mice with mRNA engineered T cells.

Authors:  David M Barrett; Yangbing Zhao; Xiaojun Liu; Shuguang Jiang; Carmine Carpenito; Michael Kalos; Richard G Carroll; Carl H June; Stephan A Grupp
Journal:  Hum Gene Ther       Date:  2011-09-23       Impact factor: 5.695

3.  The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL.

Authors:  David T Teachey; Dana A Obzut; Jonathan Cooperman; Junjie Fang; Martin Carroll; John K Choi; Peter J Houghton; Valerie I Brown; Stephan A Grupp
Journal:  Blood       Date:  2005-09-29       Impact factor: 22.113

4.  Pilot trial on the use of etanercept and methylprednisolone as primary treatment for acute graft-versus-host disease.

Authors:  Joseph P Uberti; Lois Ayash; Voravit Ratanatharathorn; Samuel Silver; Christopher Reynolds; Michael Becker; Pavan Reddy; Kenneth R Cooke; Gregory Yanik; Joel Whitfield; Dawn Jones; Raymond Hutchinson; Thomas Braun; James L M Ferrara; John E Levine
Journal:  Biol Blood Marrow Transplant       Date:  2005-09       Impact factor: 5.742

5.  The impact of soluble tumor necrosis factor receptor etanercept on the treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation.

Authors:  Gregory A Yanik; Vincent T Ho; John E Levine; Eric S White; Thomas Braun; Joseph H Antin; Joel Whitfield; Joseph Custer; Dawn Jones; James L M Ferrara; Kenneth R Cooke
Journal:  Blood       Date:  2008-07-29       Impact factor: 22.113

6.  A prospective study of G-CSF primed bone marrow as a stem-cell source for allogeneic bone marrow transplantation in children: a Pediatric Blood and Marrow Transplant Consortium (PBMTC) study.

Authors:  Haydar Frangoul; Eneida R Nemecek; Dean Billheimer; Michael A Pulsipher; Shakila Khan; Ann Woolfrey; Becky Manes; Catherine Cole; Mark C Walters; Mouhab Ayas; Yaddanapudi Ravindranath; John E Levine; Stephan A Grupp
Journal:  Blood       Date:  2007-09-07       Impact factor: 22.113

7.  Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial.

Authors:  Franco Locatelli; Peter Nöllke; Marco Zecca; Elisabeth Korthof; Edoardo Lanino; Christina Peters; Andrea Pession; Hartmut Kabisch; Cornelio Uderzo; Carmen S Bonfim; Peter Bader; Dagmar Dilloo; Jan Stary; Alexandra Fischer; Tom Révész; Monika Führer; Henrik Hasle; Monika Trebo; Marry M van den Heuvel-Eibrink; Susanna Fenu; Brigitte Strahm; Giovanna Giorgiani; Mario Regazzi Bonora; Ulrich Duffner; Charlotte M Niemeyer
Journal:  Blood       Date:  2004-09-07       Impact factor: 22.113

8.  mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia.

Authors:  David T Teachey; Cecilia Sheen; Junior Hall; Theresa Ryan; Valerie I Brown; Jonathan Fish; Gregor S D Reid; Alix E Seif; Robin Norris; Yueh J Chang; Martin Carroll; Stephan A Grupp
Journal:  Blood       Date:  2008-06-10       Impact factor: 22.113

9.  Thymic stromal-derived lymphopoietin induces proliferation of pre-B leukemia and antagonizes mTOR inhibitors, suggesting a role for interleukin-7Ralpha signaling.

Authors:  Valerie I Brown; Jessica Hulitt; Jonathan Fish; Cecilia Sheen; Marlo Bruno; Qing Xu; Martin Carroll; Junjie Fang; David Teachey; Stephan A Grupp
Journal:  Cancer Res       Date:  2007-10-15       Impact factor: 12.701

Review 10.  Novel molecular and cellular therapeutic targets in acute lymphoblastic leukemia and lymphoproliferative disease.

Authors:  Valerie I Brown; Alix E Seif; Gregor S D Reid; David T Teachey; Stephan A Grupp
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829
View more
  4 in total

1.  Challenges and opportunities for international cooperative studies in pediatric hematopoeitic cell transplantation: priorities of the Westhafen Intercontinental Group.

Authors:  Rudolph Kirk R Schultz; Kevin Scott Baker; Jaap J Boelens; Catherine M Bollard; R Maarten Egeler; Mort Cowan; Ruth Ladenstein; Arjan Lankester; Franco Locatelli; Anita Lawitschka; John E Levine; Mignon Loh; Eneida Nemecek; Charlotte Niemeyer; Vinod K Prasad; Vanderson Rocha; Shalini Shenoy; Brigitte Strahm; Paul Veys; Donna Wall; Peter Bader; Stephan A Grupp; Michael A Pulsipher; Christina Peters
Journal:  Biol Blood Marrow Transplant       Date:  2013-07-21       Impact factor: 5.742

2.  Outcomes of matched sibling donor bone marrow transplantation in children using single-agent calcineurin inhibitors as prophylaxis for graft versus host disease.

Authors:  Caitlin W Elgarten; Danielle E Arnold; Nancy J Bunin; Alix E Seif
Journal:  Pediatr Blood Cancer       Date:  2017-07-27       Impact factor: 3.167

Review 3.  The Potential of Mesenchymal Stromal Cells in Neuroblastoma Therapy for Delivery of Anti-Cancer Agents and Hematopoietic Recovery.

Authors:  Caroline Hochheuser; Nina Y Kunze; Godelieve A M Tytgat; Carlijn Voermans; Ilse Timmerman
Journal:  J Pers Med       Date:  2021-02-25

4.  Fertility preservation in female patients with hematological disorders.

Authors:  Dan Wu; Huan Shen
Journal:  BMC Pregnancy Childbirth       Date:  2022-01-22       Impact factor: 3.007
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.